The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...